
EMBECTA CORP
EMBC · NASDAQ
更新于 2026-10-15 14:38:16
- 今日最高
- $6.52
- 今日最低
- $6.19
K线图趋势,实际资料以交易页为准
关键数据
- 昨日开盘价
- $6.19
- 昨日收盘价
- $6.18
- 成交量
- 65.14万
- 市值
- $3.5亿
- 本益比(P/E)
- 4.00X
- 每股收益(EPS)
- $1.47
昨日价格区间
52周价格区间
公司概况
- 板块
- HEALTHCARE
- 行业
- Health Care
- 子行业
- MEDICAL INSTRUMENTS & SUPPLIES
- 总部
- 300 KIMBALL DRIVE, PARSIPPANY, NJ, UNITED STATES, 07054
- 国家
- US
- 上市日期
- 2022-03-21
- 财年截止
- September
- 流通股数
- 5933万
- CIK
- 0001872789
- 官方网址
- www.embecta.com
Embecta Corp (EMBC) is a leading medical technology company specializing in innovative insulin delivery systems aimed at enhancing diabetes management. Born from a spin-off of Becton, Dickinson and Company, Embecta provides a comprehensive portfolio of advanced products, including cutting-edge insulin pens and syringes tailored to improve patient outcomes. With a robust focus on operational excellence and customer satisfaction, Embecta is well-positioned to capitalize on growth opportunities in the rapidly expanding diabetes care market, strengthening its leadership in this vital sector.
财务指标
营业收入
2026-06-30
$2.71亿
2026-03-31
$2.21亿
2025-12-31
$2.61亿
2025-09-30
$2.64亿
营业支出
2026-06-30
$1.04亿
2026-03-31
$8230万
2025-12-31
$7850万
2025-09-30
$9160万
净利润
2026-06-30
$2110万
2026-03-31
-$410万
2025-12-31
$4410万
2025-09-30
$2640万
净利润率
2026-06-30
7.76%
2026-03-31
-1.84%
2025-12-31
16.88%
2025-09-30
10%
每股收益
2026-06-30
$0.56
2026-03-31
$0.27
2025-12-31
$0.71
2025-09-30
$0.50
息税折旧摊销前利润
2026-06-30
$6470万
2026-03-31
$4490万
2025-12-31
$9590万
2025-09-30
$6040万
有效税率
2026-06-30
23.55%
2026-03-31
143.15%
2025-12-31
25.12%
2025-09-30
8.96%
| 项目 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| 营业收入 | $2.71亿 | $2.21亿 | $2.61亿 | $2.64亿 |
| 营业支出 | $1.04亿 | $8230万 | $7850万 | $9160万 |
| 净利润 | $2110万 | -$410万 | $4410万 | $2640万 |
| 净利润率 | 7.76% | -1.84% | 16.88% | 10% |
| 每股收益 | $0.56 | $0.27 | $0.71 | $0.50 |
| 息税折旧摊销前利润 | $6470万 | $4490万 | $9590万 | $6040万 |
| 有效税率 | 23.55% | 143.15% | 25.12% | 8.96% |
常见问题
风险提示
股价可能大幅波动,短时间内可能出现显著涨跌。 数字资产与衍生品交易可能涉及杠杆、流动性等额外风险。 本页内容仅供参考,不构成任何投资建议。 产品可用性与访问可能因地区及适用法规而异。